Literature DB >> 1356627

Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.

Y Tomita1, H Watanabe, H Kobayashi, T Nishiyama, S Tsuji, M Fujiwara, S Sato.   

Abstract

Human renal cell cancer (RCC) cell lines, ACHN and KRC/Y, with or without exposure to cytokines, were examined for their susceptibility to lymphokine-activated killer (LAK) cells. Flow-cytometric analysis demonstrated constitutional expression of class I antigen on both cell lines, which was enhanced by interferon alpha (IFN alpha), IFN gamma and tumor necrosis factor alpha (TNF alpha). A 4-h 51Cr-release cytotoxicity assay demonstrated that pretreatment of both cell lines with IFN gamma or IFN alpha, but not with TNF alpha, decreased their susceptibility to LAK cells. IFN gamma also decreased susceptibility to natural killer cells in a 16-h 51Cr-release cytotoxicity assay. IFN gamma treatment decreased the susceptibility of ACHN cells in a dose-dependent manner. "Cold"-target competition assay clearly showed that IFN gamma- but not TNF alpha-pretreated cells compete less effectively than do untreated target cells. Pretreatment with IFN gamma, however, increased expression of intercellular adhesion molecule-1 (ICAM-1) to a degree comparable to that with TNF alpha. Northern blot analyses using a 520-base-pair ICAM-1 cDNA as a probe demonstrated that more 3.3-kb mRNA is expressed in IFN gamma- and TNF alpha-pretreated cells. These results suggest that IFN gamma-treated RCC cell lines may reduce their ability to be recognized by LAK cells, and that IFN-induced protection of RCC cell lines against LAK cells may depend upon a mechanism independent of the expression of class I antigens or ICAM-1 on tumor cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356627     DOI: 10.1007/bf01789016

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  32 in total

Review 1.  Interferon therapy in cancer: from imaginon to interferon.

Authors:  D Goldstein; J Laszlo
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

Review 2.  Interferon treatment of renal cell carcinoma. Current status and future prospects.

Authors:  S E Krown
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

Review 3.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

4.  Phase I study of recombinant tumor necrosis factor in cancer patients.

Authors:  M Blick; S A Sherwin; M Rosenblum; J Gutterman
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

5.  Susceptibility to natural killer cell-mediated cytolysis is independent of the level of target cell class I HLA expression.

Authors:  J M Leiden; B A Karpinski; L Gottschalk; J Kornbluth
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

6.  Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity.

Authors:  M W Makgoba; M E Sanders; G E Ginther Luce; E A Gugel; M L Dustin; T A Springer; S Shaw
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

7.  Responsiveness of T cells to mutant major histocompatibility complex class I antigen. II. Role of stimulator-type accessory cells with reference to interleukin 1 production.

Authors:  H Watanabe; T Saitoh; M Fujiwara
Journal:  Scand J Immunol       Date:  1989-03       Impact factor: 3.487

8.  Inflammatory cell infiltrates in human melanoma at different stages of tumor progression.

Authors:  E B Bröcker; G Zwadlo; B Holzmann; E Macher; C Sorg
Journal:  Int J Cancer       Date:  1988-04-15       Impact factor: 7.396

9.  Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.

Authors:  S Silagi; R Dutkowski; A Schaefer
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

10.  Enhanced metastases of a mouse carcinoma after in vitro treatment with murine interferon gamma.

Authors:  P Ramani; F R Balkwill
Journal:  Int J Cancer       Date:  1987-12-15       Impact factor: 7.396

View more
  6 in total

1.  BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate.

Authors:  Przemyslaw Juszczynski; Jeffery L Kutok; Cheng Li; Joydeep Mitra; Ricardo C T Aguiar; Margaret A Shipp
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

2.  Induction of transporter associated with antigen processing by interferon gamma confers endothelial cell cytoprotection against natural killer-mediated lysis.

Authors:  O Ayalon; E A Hughes; P Cresswell; J Lee; L O'Donnell; R Pardi; J R Bender
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 3.  The immunobiological effects of interleukin-2 in vivo.

Authors:  R A Janssen; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

4.  Role of intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1) in peripheral blood mononuclear cell activation by human renal carcinoma cells.

Authors:  A B Hansen; C B Andersen
Journal:  Urol Res       Date:  1994

5.  Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.

Authors:  K M Heaton; G Ju; E A Grimm
Journal:  Ann Surg Oncol       Date:  1994-05       Impact factor: 5.344

6.  Tumour necrosis factor-alpha induces an increase in susceptibility of human glioblastoma U87-MG cells to natural killer cell-mediated lysis.

Authors:  S Kondo; D Yin; J Takeuchi; T Morimura; S I Miyatake; S Nakatsu; Y Oda; H Kikuchi
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.